Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Abstract: The present invention relates to the prediction of the survival time of a patient suffering from a cancer. The inventors identified in blood from healthy donors a subpopulation of WIT cells that expresses CD73 and displays immunosuppressive phenotype and functions (i.e., production of immunosuppressive molecules and inhibition of ?ßT cell proliferation). Furthermore, they detected the presence of CD73+ ?? T cells in immune infiltrates of freshly resected breast cancer specimens. Altogether, these data suggest that part of ?? T cells infiltrated in the breast cancer microenvironment presents a regulatory phenotype characterized by CD73 expression, and are likely to display pro-tumor functions through the mechanisms they described in vitro.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.